Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
Price reaction · baseline $25.76 (2025-09-03 close) · hit after-hours · 4 other IDYA headline(s) in the window, move may be shared
day 0 close
+0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma